Speaker Profile

M.D., Ph.D., Co-Founder, Foresight Diagnostics

Biography
David Kurtz (M.D.Ph.D.) is a co-founder of Foresight Diagnostics and an Assistant Professor of Medicine (Oncology) at Stanford University. His research focuses on developing and translating methods to detect, monitor, and treat hematologic malignancies. To accomplish this, Dr. Kurtz works at the intersection of molecular biology, cancer genomics, and bioengineering to develop the next generation of cancer diagnostics. Along with Dr. Ash Alizadeh, Dr. Kurtz was one of the earliest investigators to explore the utility of tumor-derived cell-free DNA in lymphomas. He has applied multiple methodologies to detection of cell-free DNA in lymphomas, with a focus on improving the clinical utility and analytical sensitivity of these methods. Clinically, Dr. Kurtz is a medical oncologist who specializes in the treatment of non-Hodgkin lymphomas. His research program also focuses on the clinical translation of NGS tools and computational approaches for improving patient care for patients with all types of cancer.


Talk
Ultra-Sensitive MRD: A New Paradigm for Response Assessment
Dr. David Kurtz will present new data shown at ASH 2023 that compare the accuracy and prognostic utility of response assessment using ultra-sensitive ctDNA-MRD (using Foresight's PhasED-Seq MRD platform) to that of standard-of-care PETCT in lymphoma. He will also discuss implications and next steps for integration of MRD as surrogate endpoint in clinical trials.


Clinical Dx Showcase:
Foresight Diagnostics

Foresight Diagnostics is developing a novel liquid biopsy test for the measurement of minimal residual disease (MRD). The improved sensitivity of the Foresight MRD assay can provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches.

 Session Abstract – PMWC 2024 Silicon Valley

Showcase Track S2 - January 24 9.30 A.M.-1.45 P.M.,Showcase Track S2 - January 25 9.00 A.M.-4.15 P.M.,Showcase Track S2 - January 26 9.00 A.M.-2.45 P.M.


The PMWC 2024 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.

  • Clinical Dx/Oncology (including Liquid Biopsy)
  • Clinical Dx/Cardio Vascular
  • Clinical Dx/Neurodegenerative

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by JUL. 18TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required